AbbVie (LSE:0QCV) - Stock Price, News & Analysis

0QCV Stock Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.

0QCV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 57.7% below our estimate of its fair value

Earnings are forecast to grow 23.09% per year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Profit margins (8.9%) are lower than last year (20.3%)

Significant insider selling over the past 3 months

+ 1 more risk

AbbVie Inc. Competitors

AstraZeneca

LSE:AZN

UK£169.2b

Genus

LSE:GNS

UK£1.2b

GSK

LSE:GSK

UK£64.7b

Amgen

NasdaqGS:AMGN

US$140.9b

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share Price	US$164.89
52 Week High	US$182.72
52 Week Low	US$130.98
Beta	0.56
1 Month Change	-6.39%
3 Month Change	0.30%
1 Year Change	1.51%
3 Year Change	47.95%
5 Year Change	133.32%
Change since IPO	575.18%

Recent updates

Shareholder Returns

	0QCV	GB Biotechs	GB Market
7D	0.9%	-2.3%	-0.7%
1Y	1.5%	-29.4%	-1.8%

Return vs Industry: 0QCV exceeded the UK Biotechs industry which returned -29.4% over the past year.

Return vs Market: 0QCV exceeded the UK Market which returned -1.8% over the past year.

Price Volatility

Is 0QCV's price volatile compared to industry and market?
0QCV volatility
0QCV Average Weekly Movement	2.5%
Biotechs Industry Average Movement	7.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0QCV has not had significant price volatility in the past 3 months.

Volatility Over Time: 0QCV's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	50,000	Rick Gonzalez	www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
0QCV fundamental statistics
Market cap	US$291.55b
Earnings (TTM)	US$4.82b
Revenue (TTM)	US$54.32b

60.5x

P/E Ratio

5.4x

P/S Ratio

Is 0QCV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QCV income statement (TTM)
Revenue	US$54.32b
Cost of Revenue	US$16.73b
Gross Profit	US$37.59b
Other Expenses	US$32.77b
Earnings	US$4.82b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 26, 2024

Earnings per share (EPS)	2.72
Gross Margin	69.21%
Net Profit Margin	8.87%
Debt/Equity Ratio	573.6%

How did 0QCV perform over the long term?

See historical performance and comparison

Dividends

3.8%

Current Dividend Yield

220%

Payout Ratio

0QCV Stock Overview

Rewards

Risk Analysis

AbbVie Inc. Competitors

LSE:AZN

UK£169.2b

LSE:GNS

UK£1.2b

LSE:GSK

UK£64.7b

NasdaqGS:AMGN

US$140.9b

Price History & Performance

Recent News & Updates

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Recent updates

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold US$5.9m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Chairman & CEO recently sold US$25m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: US$2.73 (vs US$6.65 in FY 2022)

AbbVie Inc. Announces Chief Executive Officer Changes

Fourth quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

Full year 2023 earnings released: EPS: US$2.74 (vs US$6.65 in FY 2022)

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of US$1.55 per share at 3.8% yield

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Third quarter 2023 earnings released: EPS: US$1.00 (vs US$2.22 in 3Q 2022)

New minor risk - Profit margin trend

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie Inc. (NYSE:ABBV) acquired Mitokinin, Inc. for $655 million.

AbbVie Inc. to Report Q3, 2023 Results on Oct 27, 2023

Upcoming dividend of US$1.48 per share at 4.0% yield

Abbvie Presents Results from Phase 3 Canova Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Abbvie Inc. Announces Top-Line Results from the Phase 3 Sequence Clinical Trial Evaluating Risankizumab

AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2023

AbbVie Inc. Submits Regulatory Applications to FDA and Ema for Risankizumab (Skyrizi®) in Ulcerative Colitis

Abbvie Inc. Announces European Commission Approves AQUIPTA for the Prophylaxis of Migraine in Adults

Chairman & CEO recently sold US$12m worth of stock

Second quarter 2023 earnings released: EPS: US$1.14 (vs US$0.52 in 2Q 2022)

AbbVie Announces the British Journal of Dermatology Publishes Results from the Head-To-Head Phase 4 IMMpulse Study

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AbbVie Inc. to Report Q2, 2023 Results on Jul 27, 2023

Upcoming dividend of US$1.48 per share at 4.3% yield

AbbVie Inc. Appoints Robert A. Michael as President and Chief Operating Officer

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Shareholder Returns

Price Volatility